Vanda Pharmaceuticals (VNDA) PT Set at $36.00 by Stifel Nicolaus

Stifel Nicolaus set a $36.00 price objective on Vanda Pharmaceuticals (NASDAQ:VNDA) in a report published on Monday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.

VNDA has been the topic of a number of other research reports. Jefferies Financial Group began coverage on Vanda Pharmaceuticals in a report on Thursday, November 8th. They set a buy rating and a $26.00 target price on the stock. Zacks Investment Research cut Vanda Pharmaceuticals from a buy rating to a hold rating in a report on Wednesday, November 7th. ValuEngine upgraded Vanda Pharmaceuticals from a buy rating to a strong-buy rating in a report on Saturday, November 10th. BidaskClub cut Vanda Pharmaceuticals from a strong-buy rating to a buy rating in a report on Thursday, November 1st. Finally, TheStreet upgraded Vanda Pharmaceuticals from a c rating to a b- rating in a report on Friday, October 26th. Eight analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company. The stock currently has an average rating of Buy and an average price target of $35.38.

VNDA opened at $29.42 on Monday. The company has a market capitalization of $1.52 billion, a P/E ratio of -84.06, a PEG ratio of 3.94 and a beta of 0.87. Vanda Pharmaceuticals has a 1-year low of $13.30 and a 1-year high of $33.44.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported $0.13 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.18. The business had revenue of $49.13 million for the quarter, compared to analysts’ expectations of $49.44 million. Vanda Pharmaceuticals had a return on equity of 5.88% and a net margin of 7.06%. The company’s revenue was up 18.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.03) EPS. Analysts expect that Vanda Pharmaceuticals will post 0.21 earnings per share for the current year.

Institutional investors have recently modified their holdings of the business. Wells Fargo & Company MN lifted its stake in shares of Vanda Pharmaceuticals by 396.9% during the 3rd quarter. Wells Fargo & Company MN now owns 652,305 shares of the biopharmaceutical company’s stock worth $14,971,000 after purchasing an additional 521,040 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Vanda Pharmaceuticals by 2.5% during the 2nd quarter. Renaissance Technologies LLC now owns 1,681,250 shares of the biopharmaceutical company’s stock worth $32,028,000 after purchasing an additional 41,200 shares during the period. BlackRock Inc. lifted its stake in shares of Vanda Pharmaceuticals by 16.3% during the 2nd quarter. BlackRock Inc. now owns 4,960,924 shares of the biopharmaceutical company’s stock worth $94,506,000 after purchasing an additional 693,922 shares during the period. Xact Kapitalforvaltning AB purchased a new position in shares of Vanda Pharmaceuticals during the 2nd quarter worth $240,000. Finally, PNC Financial Services Group Inc. lifted its stake in shares of Vanda Pharmaceuticals by 25.0% during the 3rd quarter. PNC Financial Services Group Inc. now owns 279,485 shares of the biopharmaceutical company’s stock worth $6,414,000 after purchasing an additional 55,911 shares during the period. 99.33% of the stock is currently owned by institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Featured Story: What is Depreciation?

Analyst Recommendations for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply